Oracle's stock price drops 8.76% to $119.22, with bearish signals dominating the daily chart
The Cryptonomist
59m ago
Ai Focus
Oracle's stock price closed at $119.22 on Monday, down from the previous close of $130.67. The daily chart structure is bearish, with the closing price below all three moving averages and close to the lower band of the Bollinger Bands. Although a positive MACD bar chart appears on the 15-minute chart, the hourly chart remains oversold but still in a bearish state.
Helpful
No.Help

The daily chart structure of Oracle's stock is bearish, with the closing price approaching the lower band of the Bollinger Bands and below the three-day moving averages. The hourly chart readings are in an oversold zone, which complicates the situation further. However, the positive MACD bar on the 15-minute chart is merely a signal at a single point in time and does not constitute a confirmation of a bullish trend at the daily chart level.

On Monday, November 2, 2026, Oracle opened at $125.88, hit a low of $118.43 during the session, and a high of $126.50, closing at $119.22. The previous closing price was $130.67. A total of 58,484,300 shares were traded on that trading day.

Key Points

  • The daily line RSI14 is at 38.34, the daily line MACD bar chart shows -0.09, and the MACD line is at -3.26, which is below the signal line of -3.17.
  • The closing price was only slightly higher than the lower band of the daily Bollinger Bands at $119.19, and it was also below the 20-day EMA at $133.24, the 50-day EMA at $138.74, and the 200-day EMA at $159.50.
  • The hourly line RSI14 is at 26.03, which is in an oversold range; the hourly line MACD is at -3.62, which is below the signal line of -2.05.
  • The 15-minute MACD bar chart shows a value of 0.11, while the MACD line shows -2.13, which is higher than the signal line of -2.24; however, the price is still below the middle band of the 15-minute Bollinger Bands at 121.26 USD.

Oracle's stock faces a bearish daily chart structure

The daily moving averages are arranged in a bearish trend. The price is below the 20-day EMA of $133.24, followed by the 50-day EMA of $138.74 and the 200-day EMA of $159.50. This arrangement supports a bearish outlook, as all three moving averages are above the closing price.

Meanwhile, the daily RSI14 indicator is at 38.34, which is below the neutral level of 50, but it has not yet entered an oversold zone. The daily MACD bar chart has dropped from 0.86 on the previous trading day to -0.09, and the MACD line is at -3.26, which is lower than the signal line of -3.17, confirming a bearish momentum in the daily chart.

The closing price is not far above the lower band of the daily Bollinger Bands at $119.19. The middle band is at $133.57, and the upper band is at $147.95, indicating that the price is closer to the lower edge of the range rather than the middle position. The daily ATR14 has risen to $7.96, higher than the previous $7.64, suggesting that the average range of fluctuations is larger than the previous reading.

Weak hourly charts coexist with mixed execution signals.

Similarly, the hourly chart also confirms a bearish trend on the daily chart. The closing price is below the 20-period EMA at $127.34, the 50-period EMA at $129.92, and the 200-period EMA at $135.89; all of these moving averages are also in a bearish alignment.

However, the hourly chart RSI14 shows a value of 26.03, which is in an oversold area. The hourly chart MACD still shows a negative value of -3.62, which is lower than the signal line of -2.05; its bar chart indicates -1.57. Therefore, both oversold readings of RSI and slightly bullish readings of MACD exist simultaneously, rather than forming a bullish reversal.

In contrast, on the 15-minute chart, the MACD line at -2.13 is higher than the signal line at -2.24, forming a positive bar of 0.11. The 15-minute RSI14 is still in an oversold zone, at 28.07. The price is still below the 15-minute Bollinger Bands middle band of $121.26 and the 20-period EMA of $121.45; therefore, the evidence for a bullish outlook is limited to timing signals at the execution level only.

Post-market news pertains to the situation after the market closes.

Long and short conditions for the next trading session

When trading resumes, the daily pivot point is at $121.38, with the first resistance level at $124.34 and the first support level at $116.27. In terms of execution timing, the 15-minute pivot point is at $119, with the first resistance level at $119.56 and the first support level at $118.55. The closing price on Monday was above the 15-minute pivot point but below its first resistance level.

In a bullish scenario, if the price breaks through the first resistance level of $119.56 within 15 minutes, that will provide initial support. Reaching the daily pivot point of $121.38 will offer even stronger support, and if it then breaks through the first daily resistance level of $124.34, that will further strengthen the bullish trend. Nevertheless, the 20-day moving average of $133.24 will still pose a challenge above.

On the contrary, if it falls below the first support level of $118.55 over a 15-minute period as well as the intraday low of $118.43, that would weaken the bullish scenario. At that point, the first support level on the daily chart, which is $116.27, would become the next reference for downward movement. These are all conditional thresholds, not predictions.

Overall, Oracle's stock price is near the lower band of the daily Bollinger Bands, below the daily pivot point for the next trading session, and also below the bearish arranged daily moving averages. The daily ATR14 level is at $7.96, which defines the range of fluctuations. What remains to be seen is whether the positive MACD signal on the 15-minute chart can be supported by the hourly and daily charts.

Frequently Asked Questions

What is the technical analysis of Oracle's stock on a daily basis?

Oracle's stock shows a bearish daily chart structure. The closing price of $119.22 is lower than the three moving averages of the daily charts: the 20-day EMA at $133.24, the 50-day EMA at $138.74, and the 200-day EMA at $159.50. The daily RSI14 is at 38.34, and the daily MACD line is below the signal line.

Are there any positive signs for Oracle's stock?

The 15-minute MACD bar chart shows a value of 0.11, and the MACD line shows -2.13, which is higher than the signal line of -2.24. However, the price is still below the middle band of the 15-minute Bollinger Bands at 121.26 USD. On the hourly chart, the RSI14 indicator shows 26.03, indicating an oversold area, while the MACD indicator on the hourly chart remains bearish.

What key levels need to be watched for in the next trading session?

The daily pivot point is at $121.38, with the first resistance level at $124.34 and the first support level at $116.27. On the 15-minute chart, the pivot point is at $119, with the first resistance level at $119.56 and the first support level at $118.55. The lower band of the daily Bollinger Bands is at $119.19.

Disclaimer

This article is for informational purposes only and does not constitute financial advice, investment advice, or an offer or invitation to buy or sell any financial instruments. The analysis provided does not represent future results. Investing in the financial market carries a high risk of capital loss. Before making any decisions, please be sure to conduct your own research ( DYOR ) and consult a qualified financial advisor.

Cryptonomist and the author do not hold any positions in the financial instruments mentioned in this text, nor have they received any compensation from the companies reported.

This article was generated with the assistance of artificial intelligence and has been reviewed by an editorial team.

Lorenzo Marcek

Lorenzo Marcek is a financial journalist and senior crypto market analyst, renowned for his clear, data-driven reporting on digital assets. With a background in economics and over a decade of experience covering global markets, he focuses on on-chain indicators, institutional adoption trends, and crypto market fluctuations driven by macroeconomic factors. His work combines investigative journalism with technical market insights, making him a trusted source for traders seeking solid, actionable analysis.

Tip
$0
Like
0
Save
0
Views 16
HKWDB reminds readers to view blockchain rationally, stay aware of risks, and beware of virtual token issuance and speculation. All content on this site represents market information or related viewpoints only and does not constitute any form of investment advice. If you find sensitive content, please click“Report”,and we will handle it promptly。
Submit
Comment 0
Hot
Latest
No comments yet. Be the first!
Related
Ethereum is a "tokenized toll road": Reasons why Joseph Chalom is bullish on ETH
SharpLink CEO Joseph Chalom stated that the long-term logic of ETH is strengthening, and the key is no longer a single catalyst, but rather the speed of blockchain on Wall Street. He proposed three indicators for observation: the supply of stablecoins, the scale of tokenized stocks, and the volume of payment transactions between AI agents.
Coinpedia
·2026-11-03 19:35:50
8
Clarivate Announces Third Quarter 2026 Results, Calling It a Clear Path to Value Creation
Clarivate releases third-quarter results as of September 30, 2026. The company stated that driven by portfolio adjustments and AI-initiated innovation, recurring organic revenue growth has improved, and the annual contract value ( ACV ) of its intellectual property business has resumed growth. Additionally, the company completed the divestiture of its life sciences and healthcare business on October 6 and updated its financial outlook for 2026.
PR Newswire
·2026-11-03 19:24:26
16
Waters Corporation Announces Financial Results for the Third Quarter of 2026
Waters Corporation Announces Financial Results for the Third Quarter of 2026: Revenue of $1.767 Billion, Adjusted Earnings Per Share of $4.10; The Company Upsits Its Annual Revenue and Adjusted Earnings Per Share Guidance for 2026, and Indicates That It Will Provide a Growth Framework for 2027 During the Earnings Call.
PR Newswire
·2026-11-03 19:15:16
19
Clarivate Announces Third Quarter 2026 Results, Claiming to Have Paved a Clear Path for Value Creation
Clarivate Announces Third Quarter 2026 Results, Says Recurrent Organic Revenue Growth Improves Driven by Portfolio Adjustment and AI-Driven Innovation; Intellectual Property Business ACV Resumes Positive Growth; Company Also Updates 2026 Financial Prospects and Completes Sale of Life Sciences and Healthcare Business.
PR Newswire
·2026-11-03 19:15:14
18
Little-known biotech company Genmab sees success with high-risk cancer treatment bets; stock price doubles in three months
Danish biotech company Genmab has seen its stock price double within three months following a series of successful cancer drug trials. The company stated that these breakthroughs have provided new momentum for its strategy to shift from relying on royalty income to taking more control over the ownership and sales revenue of its own developed drugs.
CNBC
·2026-11-03 19:15:12
21
View More